← All candidates
45 insider filings on record.
45 filings on record.
RVMDRevolution Medicines, Inc.
NasdaqGS · Healthcare · $41.99B
$195.92
-4.36% · Sep 16
45 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 30 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$41.99B
Float
184.5M
86% public
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
40 more transactions on Pro →Context
Wall St
$200.27 avg target
+2.2% vs today · 22 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 4 quarters beat
Q1 '26−$2.29 act−$0.45
Q4 '25−$1.86 act−$0.30
Q3 '25−$1.61 act−$0.20
Q2 '25−$1.31 act−$0.19
Coverage
Better Growth Buy: Axsome vs Revolution MedicinesMotley Fool · 07-09Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?Motley Fool · 07-05Revolution’s RAS inhibitor pipeline posts more pancreatic cancer trial winsClinical Trials Arena · 07-03Why Revolution Medicines (RVMD) Is Up 6.2% After Early Zoldonrasib Pancreatic Cancer Data And What's NextSimply Wall St. · 07-03
The file stays open
45 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice